Exact Sciences To Present 10 Abstracts Demonstrating Breadth Of Its Precision Oncology Portfolio At SABCS

Benzinga · 11/25 22:37

The company said new data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally.